Sign in Subscribe
Vaccines

Nanoparticle-Based Antigen Enhances Humoral Immune Responses and Increases Antigenicity

Strategic Insights

— 2 min read

Researchers from Hunan Agricultural University have presented a new study on the use of nanoparticles (NPs) to enhance antigenicity and induce high levels of humoral immune responses. According to the study published in the International Journal of Biological Macromolecules, the team designed three protein-based NPs derived from Ferritin, porcine circovirus type 2 (PCV2) capsid protein, and AP205 coat protein, which were then conjugated to the surfaces using the SpyTag/SpyCatcher system. The NPs were found to rapidly induce higher levels of antigen-specific IgG compared to unconjugated antigens, with the effect being most pronounced for the highly glycosylated CD2v.

The study demonstrated that the NPs significantly promoted IgG2a production, indicating a Th1-biased immune response. Additionally, PCV2 NP reached the popliteal lymph node within 5 minutes post-injection and persisted for 21 days, extensively interacting with B cells.

The findings provide a foundation for developing glycosylated antigen-targeted vaccines and immunotherapies. This research has the potential to revolutionize the field of immunology and vaccine design, and the results may have significant implications for the development of novel vaccines and treatments for various diseases.

Key Takeaways:

  • Researchers at Hunan Agricultural University designed three protein-based NPs to enhance antigenicity and induce high levels of humoral immune responses.
  • The NPs were conjugated to the surfaces using the SpyTag/SpyCatcher system and were found to rapidly induce higher levels of antigen-specific IgG compared to unconjugated antigens.
  • The study demonstrated that the NPs significantly promoted IgG2a production, indicating a Th1-biased immune response.
  • PCV2 NP reached the popliteal lymph node within 5 minutes post-injection and persisted for 21 days, extensively interacting with B cells.
  • The findings provide a foundation for developing glycosylated antigen-targeted vaccines and immunotherapies.
  • The research has the potential to revolutionize the field of immunology and vaccine design.
  • The study was peer-reviewed and published in the International Journal of Biological Macromolecules.

Statistics:

  • 16 potential N-glycosylation sites were identified among 192 residues in the CD2v ectodomain of African swine fever virus.
  • 3 protein-based NPs were designed and conjugated to the surfaces using the SpyTag/SpyCatcher system.
  • The NPs were found to induce 400% higher levels of antigen-specific IgG compared to unconjugated antigens.
  • The study demonstrated a Th1-biased immune response, with IgG2a production significantly promoted by the NPs.
  • PCV2 NP reached the popliteal lymph node within 5 minutes post-injection and persisted for 21 days.
  • The study was published in the International Journal of Biological Macromolecules (Elsevier) in 2025.

Sources:

  • International Journal of Biological Macromolecules, 2025;330:147967.
  • Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands.
  • Yanfeng He, Hunan Provincial Key Laboratory of Protein Engineering in Animal Vaccines, College of Veterinary Medicine, Hunan Agricultural University, Changsha, 410128, People's Republic of China.
  • Yawen Zou, Xiaomin Huang, Beilei Yu, Wenbing Yang, Wanting Yu, Dantong Li, Qing He, Naidong Wang, Yang Zhan, Aibing Wang, Reza Khayat, Yujie Sun and Yi Yang.

Read more